533 related articles for article (PubMed ID: 27080976)
1. Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD.
Xie Y; Bowe B; Li T; Xian H; Balasubramanian S; Al-Aly Z
J Am Soc Nephrol; 2016 Oct; 27(10):3153-3163. PubMed ID: 27080976
[TBL] [Abstract][Full Text] [Related]
2. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury.
Xie Y; Bowe B; Li T; Xian H; Yan Y; Al-Aly Z
Kidney Int; 2017 Jun; 91(6):1482-1494. PubMed ID: 28237709
[TBL] [Abstract][Full Text] [Related]
3. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.
Lazarus B; Chen Y; Wilson FP; Sang Y; Chang AR; Coresh J; Grams ME
JAMA Intern Med; 2016 Feb; 176(2):238-46. PubMed ID: 26752337
[TBL] [Abstract][Full Text] [Related]
4. Associations of Proton-Pump Inhibitors and H2 Receptor Antagonists with Chronic Kidney Disease: A Meta-Analysis.
Wijarnpreecha K; Thongprayoon C; Chesdachai S; Panjawatanana P; Ungprasert P; Cheungpasitporn W
Dig Dis Sci; 2017 Oct; 62(10):2821-2827. PubMed ID: 28836158
[TBL] [Abstract][Full Text] [Related]
5. Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans.
Xie Y; Bowe B; Li T; Xian H; Yan Y; Al-Aly Z
BMJ Open; 2017 Jul; 7(6):e015735. PubMed ID: 28676480
[TBL] [Abstract][Full Text] [Related]
6. Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease.
Klatte DCF; Gasparini A; Xu H; de Deco P; Trevisan M; Johansson ALV; Wettermark B; Ärnlöv J; Janmaat CJ; Lindholm B; Dekker FW; Coresh J; Grams ME; Carrero JJ
Gastroenterology; 2017 Sep; 153(3):702-710. PubMed ID: 28583827
[TBL] [Abstract][Full Text] [Related]
7. Non-indicated initiation of proton pump inhibitor and risk of adverse outcomes in patients with underlying chronic kidney disease: a nationwide, retrospective, cohort study.
Kim SG; Cho JM; Han K; Joo KW; Lee S; Kim Y; Cho S; Huh H; Kim M; Kang E; Kim DK; Park S
BMJ Open; 2024 Jan; 14(1):e078032. PubMed ID: 38286693
[TBL] [Abstract][Full Text] [Related]
8. Association between Monocyte Count and Risk of Incident CKD and Progression to ESRD.
Bowe B; Xie Y; Xian H; Li T; Al-Aly Z
Clin J Am Soc Nephrol; 2017 Apr; 12(4):603-613. PubMed ID: 28348030
[TBL] [Abstract][Full Text] [Related]
9. Proton-pump inhibitor vs. H2-receptor blocker use and overall risk of CKD progression.
Cholin L; Ashour T; Mehdi A; Taliercio JJ; Daou R; Arrigain S; Schold JD; Thomas G; Nally J; Nakhoul NL; Nakhoul GN
BMC Nephrol; 2021 Jul; 22(1):264. PubMed ID: 34266395
[TBL] [Abstract][Full Text] [Related]
10. The use of anti-ulcer agents and the risk of chronic kidney disease: a meta-analysis.
Sun J; Sun H; Cui M; Sun Z; Li W; Wei J; Zhou S
Int Urol Nephrol; 2018 Oct; 50(10):1835-1843. PubMed ID: 29948864
[TBL] [Abstract][Full Text] [Related]
11. Proton pump inhibitors and chronic kidney disease risk: a comparative study with histamine-2 receptor antagonists.
Kweon T; Kim Y; Lee KJ; Seo WW; Seo SI; Shin WG; Shin DH
Sci Rep; 2023 Dec; 13(1):21169. PubMed ID: 38036592
[TBL] [Abstract][Full Text] [Related]
12. Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retrospective Cohort Study.
Hart E; Dunn TE; Feuerstein S; Jacobs DM
Pharmacotherapy; 2019 Apr; 39(4):443-453. PubMed ID: 30779194
[TBL] [Abstract][Full Text] [Related]
13. Particulate Matter Air Pollution and the Risk of Incident CKD and Progression to ESRD.
Bowe B; Xie Y; Li T; Yan Y; Xian H; Al-Aly Z
J Am Soc Nephrol; 2018 Jan; 29(1):218-230. PubMed ID: 28935655
[TBL] [Abstract][Full Text] [Related]
14. Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and Hip Fracture Risk among Patients on Hemodialysis.
Vangala C; Niu J; Lenihan CR; Mitch WE; Navaneethan SD; Winkelmayer WC
Clin J Am Soc Nephrol; 2018 Oct; 13(10):1534-1541. PubMed ID: 30262672
[TBL] [Abstract][Full Text] [Related]
15. Proton pump inhibitor use and progression to major adverse renal events: a competing risk analysis.
Grant CH; Gillis KA; Lees JS; Traynor JP; Mark PB; Stevens KI
QJM; 2019 Nov; 112(11):835-840. PubMed ID: 31251364
[TBL] [Abstract][Full Text] [Related]
16. Proton pump inhibitors are associated with increased risk of development of chronic kidney disease.
Arora P; Gupta A; Golzy M; Patel N; Carter RL; Jalal K; Lohr JW
BMC Nephrol; 2016 Aug; 17(1):112. PubMed ID: 27487959
[TBL] [Abstract][Full Text] [Related]
17. Histamine H2-Blocker and Proton Pump Inhibitor Use and the Risk of Pneumonia in Acute Stroke: A Retrospective Analysis on Susceptible Patients.
Arai N; Nakamizo T; Ihara H; Koide T; Nakamura A; Tabuse M; Miyazaki H
PLoS One; 2017; 12(1):e0169300. PubMed ID: 28085910
[TBL] [Abstract][Full Text] [Related]
18. Cognitive Impairment and Progression of CKD.
Kurella Tamura M; Yaffe K; Hsu CY; Yang J; Sozio S; Fischer M; Chen J; Ojo A; DeLuca J; Xie D; Vittinghoff E; Go AS;
Am J Kidney Dis; 2016 Jul; 68(1):77-83. PubMed ID: 26972681
[TBL] [Abstract][Full Text] [Related]
19. Duration and dosing of Proton Pump Inhibitors associated with high incidence of chronic kidney disease in population-based cohort.
Rodríguez-Poncelas A; Barceló MA; Saez M; Coll-de-Tuero G
PLoS One; 2018; 13(10):e0204231. PubMed ID: 30332411
[TBL] [Abstract][Full Text] [Related]
20. Proton-Pump Inhibitors and Risk of Calcium Pyrophosphate Deposition in a Population-Based Study.
Liew JW; Peloquin C; Tedeschi SK; Felson DT; Zhang Y; Choi HK; Terkeltaub R; Neogi T
Arthritis Care Res (Hoboken); 2022 Dec; 74(12):2059-2065. PubMed ID: 35245410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
